[¿Â¶óÀÎ] 2023 ´ëÇÑÇ÷¾×ÇÐȸ ºÐ±âÁý´ãȸ : 2023-08-24
±³À°ÀÏÀÚ : 2023-08-24
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ : [¿Â¶óÀÎ] 2023 ´ëÇÑÇ÷¾×ÇÐȸ ºÐ±âÁý´ãȸ
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 80¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 50,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 24ÀÏ A 17:00~18:00 Immune thrombocytopenia ÀåÁØÈ£(¼º±Õ°üÀÇ)
±³À°½Ã°£ 08¿ù 24ÀÏ A 18:00~18:30 Ç÷¾×¾Ï À¯Àü °Ë»ç¹ý ¼±Åðú Àû¿ë-1 ±èÇö¿µ(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 08¿ù 24ÀÏ A 18:30~19:00 CML(chronic myeloid leukemia) MRD(minimal residual disease) monitoring ÃÖÀ¯Á¤(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 08¿ù 24ÀÏ A 19:00~19:30 Treatment of patients with lenalidomide-exposed or refractory MM(multiple myeloma) ÀÌÁöÀ±(¼¿ïÀÇ´ë )
±³À°½Ã°£ 08¿ù 24ÀÏ A 19:30~20:30 cytopenia among patients with CP(chronic phase) CML(chronic myeloid leukemia) treated with TKIs ±è°¡¿µ(°¡Å縯ÀÇ´ë )